BIOTECHNOLOGY
1 min.Read

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

Results include support for utility of Immunotherapy Response Score for individualized treatment decision-making in NSCLC and pan-tumor predictive power of Antibody-Drug Conjugate Treatment Response Score

Strata Oncology, Inc. (“Strata”), a next-generation precision oncology company enabling smarter cancer treatment, today announced that it will present new data in scientific posters at the 2023 North America Conference on Lung Cancer (NACLC) taking place December 1-3, 2023 in Chicago, Illinois and the San Antonio Breast Cancer Symposium (SABCS) taking place December 5-9, 2023 in San Antonio, Texas.

The data to be presented includes results for innovative, proprietary predictive biomarkers for response to anti-PD-1/PD-L1 immunotherapy and antibody-drug conjugates (ADCs) — the Immunotherapy Response Score (IRS) and ADC Treatment Response Score (ADC TRS), respectively. Strata has developed these biomarkers and others using data collected through an observational clinical trial protocol called the Strata Trial® (NCT03061305). All of these biomarkers take advantage of the company’s unique molecular profiling platform that combines DNA and quantitative RNA sequencing on a single small tumor tissue sample.

“Many of the most exciting recent advances in cancer treatment – such as immunotherapy and antibody-drug conjugates – do not currently have biomarkers that can accurately predict response. Strata has taken on this challenge by advancing multivariate predictive treatment selection algorithms that capture the complex biology required for a tumor response,” said Scott Tomlins, M.D., Ph.D., Strata Oncology co-founder and chief medical officer. “We believe that this type of strategy is required to fully realize the potential of precision oncology to improve patient outcomes. We look forward to sharing our latest advances at NACLC and SABCS.”

Poster presentation details are below. Both posters will be available on the Strata Oncology website following the presentation.

North America Conference on Lung Cancer (NACLC)

Poster Title: Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)

Session Date and Time: Saturday, December 2, 5:40-6:55 PM CST

San Antonio Breast Cancer Symposium (SABCS)

Poster Title: A Multivariate Biomarker to Guide Antibody-Drug Conjugate Selection and Provide Insight on Response Differences Across Breast Cancer Subtypes

Session Date and Time: Wednesday, December 6, 12:00-2:00 PM CST

SourceStrata Oncology

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330